7 completed, 7 recruiting, 2 terminated, 1 active not recruiting. 9 Not applicable, 4 Phase 1, 1 Early Phase 1, 1 Phase 2, 1 Phase 4.
Follow Primary Progressive Nonfluent Aphasia: new trials by email Literature Review of Primary Progressive Nonfluent Aphasia trials Research Report on Primary Progressive Nonfluent Aphasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intervention for Communication Quality of Life in Primary Progressive Aphasia Multicomponent Lexical Retrieval Cascade Training, Multicomponent Video Implemented Script Training in Aphasia - Primary Progressive Aphasia(PPA), Semantic Dementia | Not applicable | Recruiting | Maya Henry | 30 | 2026-04-01 | 2026-04-21 |
| Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia Active tDCS + Language Therapy, Sham tDCS + Language Therapy - Primary Progressive Aphasia, Logopenic Progressive Aphasia | Phase 2 | Recruiting | Johns Hopkins University | 180 | 2024-02-13 | 2026-05-05 |
| Primary Progressive Aphasia Multicomponent Language Treatment Study Multicomponent Lexical Retrieval Training (Multi-LRT), Multicomponent Video Implemented Script Training in Aphasia (Multi-VISTA), Multicomponent Communication Partner Training (Multi-CPT) - Primary Progressive Aphasia, Semantic Dementia | Not applicable | Enrolling by invitation | University of Texas at Austin | 21 | 2023-05-02 | 2025-10-08 |
| tDCS and Speech Therapy for Motor Speech Disorders Caused by FTLD Syndromes: a Feasibility Study Halo Neuroscience Neurostimulator - Nonfluent Aphasia, Progressive, Primary Progressive Nonfluent Aphasia | Not applicable | Withdrawn | University of California, San Francisco | 2022-07-01 | 2022-08-19 | |
| rTMS as a Treatment for PPA Active rTMS, SHAM rTMS - Logopenic Variant Primary Progressive Aphasia, Non-Fluent Primary Progressive Aphasia | Early Phase 1 | Completed | Massachusetts General Hospital | 12 | 2019-12-01 | 2022-04-07 |
| BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES BIIB092, Placebo - Primary Tauopathies, Corticobasal Degeneration Syndrome | Phase 1 | Terminated | University of California, San Francisco | 22 | 2018-09-12 | 2019-12-19 |
| Transcranial Magnetic Stimulation in Nonfluent/Agrammatic Variant Primary Progressive Aphasia Active iTBS, Sham iTBS - Primary Progressive Nonfluent Aphasia | Not applicable | Terminated | University of British Columbia | 2 | 2018-09-01 | 2022-03-03 |
| Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech AV-1451 - PPA, Non-fluent Aphasia | Phase 4 | Recruiting | Mayo Clinic | 50 | 2018-07-01 | 2025-11-12 |
| The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech Testing protocol for the study - Apraxia of Speech, Non-fluent Aphasia | Recruiting | Mayo Clinic | 47 | 2017-08-01 | 2026-05-01 | |
| A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia AADvac1 40 µg, AADvac1 160 µg - Primary Progressive Nonfluent Aphasia | Phase 1 | Unknown | Axon Neuroscience SE | 33 | 2017-07-31 | 2019-11-14 |
| Treatment for Speech and Language in Primary Progressive Aphasia Lexical Retrieval Training (LRT), Video-Implemented Script Training for Aphasia (VISTA) - Primary Progressive Aphasia, Semantic Dementia | Not applicable | Active not recruiting | University of Texas at Austin | 60 | 2017-07-01 | 2025-11-13 |
| The Swedish BioFINDER 2 Study Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau - Dementia, Alzheimer Disease | Not applicable | Recruiting | Skane University Hospital | 2950 | 2017-05-15 | 2026-04-06 |
| A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease Ketogenic medium chain triglyceride drink (MCT drink), Placebo - Alzheimer's Disease, Primary Progressive Non-fluent Aphasia | Not applicable | Completed | University of British Columbia | 43 | 2016-09-01 | 2026-04-23 |
| Diagnosing Frontotemporal Lobar Degeneration Observational Study - Corticobasal Syndrome, Progressive Supranuclear Palsy | Recruiting | University Health Network, Toronto | 100 | 2015-08-01 | 2025-03-30 | |
| Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) FTLD, Progressive Supranuclear Palsy (PSP) | Completed | University of California, San Francisco | 1489 | 2014-09-01 | 2021-05-21 | |
| Communication Bridge Speech Therapy Research Study Monthly Check-in Session - Primary Progressive Aphasia, Frontotemporal Dementia | Not applicable | Completed | University of Chicago | 57 | 2013-03-01 | 2024-09-19 |
| PiB PET Scanning in Speech and Language Based Dementias C-11 PiB, F-18 FDG - PPA, Primary Progressive Aphasia | Phase 1 | Completed | Mayo Clinic | 168 | 2010-03-01 | 2015-12-22 |
| Davunetide (AL-108) in Predicted Tauopathies - Pilot Study davunetide (AL-108, NAP), Placebo nasal spray - Predicted Tauopathies, Including, Progressive Supranuclear Palsy | Phase 1 | Completed | University of California, San Francisco | 12 | 2010-01-01 | 2019-04-05 |
| Language Treatment for Progressive Aphasia Errorless learning - Primary Progressive Aphasia, Nonfluent Progressive Aphasia | Not applicable | Completed | Baycrest | 7 | 2009-08-01 | 2015-01-27 |
| Language in Primary Progressive Aphasia Primary Progressive Aphasia | Recruiting | Northwestern University | 500 | 2007-05-01 | 2026-02-27 |
Frontotemporal Dementia (13) · Aphasia, Primary Progressive (11) · Aphasia (9) · Corticobasal Degeneration (5) · Frontotemporal Lobar Degeneration (5) · Supranuclear Palsy, Progressive (5) · Aphasia, Broca (4) · Apraxias (4) · Pick Disease of the Brain (4) · Neurodegenerative Diseases (3) · Alzheimer Disease (2) · Amyotrophic Lateral Sclerosis (2) · Color Vision Defects (2) · Memory Disorders (2)
Brain Diseases (20) · Central Nervous System Diseases (20) · Communication Disorders (20) · Mental Disorders (20) · Metabolic Diseases (20) · Nervous System Diseases (20) · Neurobehavioral Manifestations (20) · Neurocognitive Disorders (20) · Neurologic Manifestations (20) · Nutritional and Metabolic Diseases (20) · Pathological Conditions, Signs and Symptoms (20) · Proteostasis Deficiencies (20) · Signs and Symptoms (20) · Speech Disorders (20) · TDP-43 Proteinopathies (20)
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (1) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1) · AADvac1 (1) · Language Therapy (1) · Observation (1) · Speech Therapy (1) · Therapeutics (1) · davunetide (1) · gosuranemab (1)
University of California, San Francisco (4) · Mayo Clinic (3) · University of British Columbia (2) · University of Texas at Austin (2) · Axon Neuroscience SE (1) · Baycrest (1) · Johns Hopkins University (1) · Massachusetts General Hospital (1) · Maya Henry (1) · Northwestern University (1) · Skane University Hospital (1) · University Health Network, Toronto (1) · University of Chicago (1)
United States (13) · Canada (6) · Germany (1) · Sweden (1)
Maya L Henry, PhD (3) · Adam Boxer, MD, PhD (1) · Adam L Boxer, MD, PhD (1) · Adam L. Boxer, M.D., Ph.D. (1) · Emily J Rogalski, PhD (1) · Erik Stomrud, MD, Phd (1) · Fidel Vila-Rodriguez, MD (1) · Haakon Nygaard, MD, PhD (1) · Howard Feldman, MD (1) · Jennifer Whitwell, PhD (1) · Keith A Josephs, M.D. MST, MSc (1) · Keith Josephs, MD (1) · Kyrana Tsapkini, PhD. (1) · Maria C Tartaglia, M.D. (1) · Maria Luisa Gorno Tempini, MD PhD (1)
PMID 33441454, PMID 33827960, PMID 34937781, PMID 35492244, PMID 35790423, PMID 41864233
2017 (1), R01AG075111 (1), R01AG077444 (1), R01DC012519 (1), R01DC016291 (1), R56DC016291 (1), U54NS092089 (1)